Therefore, oral NLRP3 inhibitors [133,134,135] clinically used for therapy of severe gout, arthritis, and prevention of heart failure (i.e., dapansutrile) are currently proposed in the USA as a strategy to prevent acute respiratory distress syndrome and cardiovascular diseases in COVID-19 [136]. Here, NLRP3 is linked to heart failure.